EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Overcoming Challenges in Dengue Vaccine Development: Advanced Delivery Approaches

Anindita Sengupta, Jayanta Bhattacharyya iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c00937 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Anindita Sengupta und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Biomedical Engineering, Indian Institute of Technology, Delhi, New Delhi 110016, India. Hauptthemen laut MEDLINE: Dengue Vaccines, Dengue Virus, Vaccine Development, Dengue. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 110 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dengue virus (DENV), comprising four antigenically distinct serotypes, remains a major global health problem. Vaccine development is hindered by immunological barriers, including antibody-dependent enhancement (ADE), original antigenic sin, and the requirement for balanced, long-lasting immunity against all serotypes. This review focuses on emerging strategies that improve vaccine-induced immune memory through rational antigen design and advanced delivery systems. Nanoparticles, including lipid-based carriers, polymeric particles, and virus-like particles (VLPs), support antigen stability, promote dendritic cell (DC) uptake, and enhance delivery to the lymph node. Injectable hydrogels and responsive biomaterials provide sustained antigen release, promoting germinal center (GC) formation and memory B and T-cell memory responses. Targeted delivery using ligands for C-type lectins or mannose receptors further increases the antigen presentation efficiency. Potent adjuvants, including toll- like receptor (TLR) agonists (Poly I:C, CpG, and R848) and saponin-based molecules (QS-21, MPL), activate innate immune sensors and guide Th1-type adaptive responses. New vaccine formulations, including multiepitope peptide vaccines, mRNA and DNA constructs, and extracellular vesicle (EV)-based carriers derived from DCs or milk, offer cell-free, scalable, and immune system-activating platforms. Furthermore, in silico approaches facilitate epitope identification, MHC-binding prediction, and immune response simulation. Collectively, these strategies address recent challenges and support the development of dengue vaccines that offer enhanced safety and durable immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dengue VaccinesDengue VirusVaccine DevelopmentDengueDrug Delivery SystemsHumansAnimalsNanoparticlesDendritic CellsHydrogelsNanovaccinesImmunologic MemoryVaccines, Virus-Like ParticleProtein Subunit Vaccines

Stichwörter der Autor:innen

TLR agonistsadvanced delivery systemscell-free vaccinedengue vaccinehydrogelsimmune modulatorsin silico modelnanoparticlessustained release

Substanzen

Dengue VaccinesHydrogelsNanovaccinesVaccines, Virus-Like ParticleProtein Subunit Vaccines

Autor:innen und Institutionen

  • Centre for Biomedical Engineering, Indian Institute of Technology, Delhi, New Delhi 110016, India.
  • Department of Biomedical Engineering, All India Institute of Medical Science, Delhi, New Delhi 110029, India.

ORCID-Profile: Jayanta Bhattacharyya

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Sengupta, A., & Bhattacharyya, J. (2026). Overcoming Challenges in Dengue Vaccine Development: Advanced Delivery Approaches. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00937

Vancouver

Sengupta A, Bhattacharyya J. Overcoming Challenges in Dengue Vaccine Development: Advanced Delivery Approaches. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c00937

BibTeX
@article{Sengupta2026,
  author = {Sengupta, Anindita and Bhattacharyya, Jayanta},
  title = {Overcoming Challenges in Dengue Vaccine Development: Advanced Delivery Approaches},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c00937}
}
Kostenlos starten →